Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Pemetrexed in Pretreated Advanced Non-squamous NSCLC
NCT02974933Phase 2Unknown
- Sponsor
- Wuling
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Wuling. Primary endpoint: Progression-Free Survival at 4 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02974933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974933.